Newly developed shelf-stable synthetic blood could change battlefield medicine Military Times Nawigacja wpisu With $50M from Flagship Pioneering, Serif strives to write new chapter for DNA medicines – Fierce Biotech Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial – Nature
